Baillie Gifford & Co
EBS icon

Baillie Gifford & Co’s Emergent Biosolutions EBS Stock Holding History

Baillie Gifford & Co’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-385
Closed -$4.55K – 464
2022
Q4 		$4.55K Hold
385
– – ﹤0.01% 453
2022
Q3 		$8K Hold
385
– – ﹤0.01% 423
2022
Q2 		$12K Hold
385
– – ﹤0.01% 393
2022
Q1 		$16K Hold
385
– – ﹤0.01% 390
2021
Q4 		$17K Hold
385
– – ﹤0.01% 397
2021
Q3 		$19K Sell
385
-38
-9% -$2.3K ﹤0.01% 377
2021
Q2 		$27K Hold
423
– – ﹤0.01% 328
2021
Q1 		$39K Buy
423
+16
+4% +$1.64K ﹤0.01% 292
2020
Q4 		$36K Buy
+407
New +$37.4K ﹤0.01% 284

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baillie Gifford & Co's EBS Position: Q1 2023 in Review

Baillie Gifford & Co sold out of Emergent Biosolutions (EBS) in Q1 2023, closing a stake of 385 shares — an estimated $4.55K sold.

Baillie Gifford & Co first reported a position in EBS in Q4 2020 and held it in 9 quarters. The position peaked at $39K in Q1 2021. 191 funds tracked by Wall St. Rank hold EBS as of Q1 2023.

  • Baillie Gifford & Co reported no remaining Emergent Biosolutions position as of Q1 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 385 Emergent Biosolutions shares in Q1 2023, an estimated $4.55K.
  • Baillie Gifford & Co first reported a position in Emergent Biosolutions in Q4 2020 and held it in 9 quarters.
  • Baillie Gifford & Co's Emergent Biosolutions position peaked at $39K in Q1 2021.
  • 191 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2023.

Based on Baillie Gifford & Co's 13F filing for Q1 2023, filed 3 May 2023.